Genentech

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Retrieved on: 
Sunday, April 7, 2024
BNTX, Survival, Entrepreneurship, Genentech, Disease, BioNTech, Patient, Neoplasm, Tissue, Messenger, PDAC, Roche, Uridine, Safety, Cancer, De novo, Recurrence, Blood, Vaccine

The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.

Key Points: 
  • The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.
  • The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
  • “These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need.
  • Over 80% of the vaccine-induced neoantigen-specific T cells could still be detected up to three years post administration in patients with an immune response.

Affimed Reports 2023 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 28, 2024
Research, EGFR, GVHD, NSCLC, Genentech, ASH, AML, PD, Disease, International, International Financial Reporting Standards, Patient, Webcast, EFS, EDT, CRS, Cancer, Record, Insurance, Trial of the century, Bank statement, Investment, Safety, Workforce, Roivant Sciences, PFS, IASB, Hodgkin lymphoma, Book, NK, HL, Cytokine release syndrome

MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.

Key Points: 
  • MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
  • Based on the promising results, Affimed expanded enrollment in this cohort to 40 patients.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on March 28, 2024, at 8:30 a.m. EDT / 13:30 CET to discuss full year 2023 financial results and corporate developments.

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Retrieved on: 
Tuesday, March 26, 2024
Development, Growth, Skin cancer, Immunotherapy, Genentech, Philip, Patient, Lung, RP1, Skin, Cancer, Melanoma, Retirement, Marketing, BLA

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.

Key Points: 
  • Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024.
  • Mr. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors.
  • Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer.
  • Prior to joining Replimune, Dr. Patel served as franchise head for lung, skin and rare cancers at Genentech.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neuroscience, Juno Therapeutics, Genentech, Cornell University, Heredity, Patient, Carmustine, Acquisition, Allergy, Senior, Research and development, Therapy, Drug development, Rituximab, Management

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.
  • Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
  • “It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
  • “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”
    Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics.

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
University of Illinois Urbana-Champaign, Drug discovery, Schering-Plough, Patient, Genentech, Acquisition, Cancer, Laboratory, Biology, Northern Illinois University, Stanford University, Amgen, Pharmaceutical industry

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.
  • “On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board,” said Ben Zeskind, Chief Executive Officer, Immuneering Corporation.
  • From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation.
  • in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Boston Scientific, Werewolf, Growth, Genentech, Strategic management, CFO, Business, Novartis, Trustee, Patient, Chairperson, Tuck School of Business, CBO, Sale, Business development, Acquisition, University, IPO, Belharra, Columbia Law School, Doctor of Philosophy, Senior, MBA, Clinical trial, Therapy, Guidant, DePauw University, Claremont McKenna College, Drug resistance, Celgene, FDA, Economics, Corporation, Management

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
  • "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry.
  • Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership.

IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cantor Fitzgerald, Ohio State University, Development, J. P. Morgan, Information technology, Novo Nordisk, NSCLC, Genentech, University, Brad, Patient, Research, Sale, Acquisition, Lung cancer, Research and development, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, RBC Capital Markets, Forma, Drug resistance, Pharmaceutical industry

Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.

Key Points: 
  • Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.
  • He played a key role in the company's evolution from early research to a global commercial oncology company, and its subsequent acquisition by Takeda.
  • He led Selecta through several significant financing and strategic transactions, including a $730 million licensing agreement for its lead program.
  • “I look forward to working with Tim, Ben, and the team at IDRx to grow the Company with the backbone of IDRX-42,” said Mr. Dahms.

Global Leaders in Cancer Research and Biotech Join The Mark Foundation for Cancer Research's Scientific Advisory and Industry Advisory Committees

Retrieved on: 
Tuesday, April 2, 2024
Molecule, Medicine, Cancer Research UK, FRS, Weill Cornell Medicine, Francis Crick Institute, B cell, Patient, Investment, Children's National Hospital, Therapy, Research, Biotechnology, Genentech, Dana–Farber Cancer Institute, Committee, Trial of the century, University, University College Hospital, Metastasis, Multiple sclerosis, Drug discovery, MBBS, Chairperson, MD, University College London, Senior, FRCP, University of California, Berkeley, Hospital, Nationwide Children's Hospital, Marker beacon, Diagnosis, Lung cancer, Ludwig Cancer Research, University of Pennsylvania, Doctor of Philosophy, BTK, GV (company), Celera Corporation, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

Key Points: 
  • The committee assists the foundation in reviewing its scientific goals and grant applications, as well as providing strategic advice and support for its research programs and investments.
  • "The outstanding researchers on our advisory committees provide invaluable guidance and insight to help steer its programs toward success and impact."
  • "The Mark Foundation's funding of high-risk, high-impact research is essential in the quest to achieve real breakthroughs in cancer research," said Johanna Joyce, PhD.
  • "I am honored to join the Scientific Advisory Committee, to support the next generations of scientists and projects that will revolutionize treatments for patients."

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Retrieved on: 
Tuesday, March 12, 2024
Toxicity, NSCLC, Genentech, Disease, Fast track (FDA), Diabetes, Patient, Merck, Pembrolizumab, Cancer, Senior, Clinical trial, Intellectual property, Patent, PD-L1, FDA, PD-1, Pharmaceutical industry

AUSTIN, Texas, March 12, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex's lead drug candidate, Reqorsa® Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037.

Key Points: 
  • These patents are applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials.
  • Genprex expects to complete enrollment in the Phase 1 dose escalation portion of the Acclaim-2 study in the second half of 2024.
  • The Acclaim-3 study has two portions - a Phase 1 dose escalation portion and a Phase 2 expansion portion.
  • Genprex was granted FDA Fast Track Designation and Orphan Drug Designation for the Acclaim-3 patient population.